Ingo Kleiter
|
CURRICULUM VITAE |
|||
|
Name, first name |
Prof. Kleiter, Ingo |
||
|
Date/Place of Birth: |
29.10.1972 / Erlangen, Germany |
||
|
Affiliations: |
1 Marianne-Strauß-Klinik, 2 Ruhr-University Bochum, 44791 Bochum, Germany |
||
|
Present Position: |
Medical Director |
||
|
Professional qualifications |
Date |
Place |
|
|
Doctor´s thesis (“Dr. med.”) |
2000 |
University of Erlangen-Nürnberg, Germany |
|
|
Medical license acquired (“Approbation”) |
2001 |
Würzburg, Germany |
|
|
Board certification Neurology |
2007 |
München, Germany |
|
|
Assistant Professor for Clinical and Experimental Neuroimmunology |
2011 |
Ruhr-University Bochum, Germany |
|
|
Associate Professor |
2018 |
Ruhr-University Bochum, Germany |
|
|
Education/professional experience |
From |
To |
Place |
|
Medical School |
1992 |
1999 |
University of Erlangen-Nürnberg, Germany |
|
Resident |
2000 |
2003 |
Department of Neurology, University of Regensburg, Germany |
|
Research fellow |
2003 |
2004 |
Institute of Genetics, University of Cologne, Germany |
|
Resident, since 2007 attending |
2004 |
2011 |
Department of Neurology, University of Regensburg, Germany |
|
Attending (consultant) |
2011 |
2017 |
Department of Neurology, Ruhr-University Bochum, Germany |
|
Medical Director |
2017 |
Ongoing |
Marianne-Strauß-Klinik, Germany |
|
Membership of medical scientific societies / consortia |
Since |
||
|
2003 |
Deutsche Gesellschaft für Neurologie (DGN), Germany |
||
|
2008 |
Deutsche Gesellschaft für Klinische Neurophysiologie (DGKN), Germany Certificates: EMG, EP, Ultrasound |
||
|
2009 |
Neuromyelitis optica study group (NEMOS), Germany |
||
|
2013 |
International Clinical Consortium, Guthy Jackson Foundation, Los Angeles, USA |
||
Selected publications
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. NEJM 2019 Nov 28;381(22):2114-2124.
Kleiter I, Gahlen A, Borisow N, …, NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018 Sep 26;5(6):e504.
Kleiter I, Gahlen A, Borisow N, …, NEMOS (Neuromyelitis Optica Study Group). Therapy of neuromyelitis optica exacerbations:
a retrospective evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 2016; 79: 206-216.
Stellmann J, Krumbholz M, Friede T, …, Kleiter I. Immunotherapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017;88(8):639-647
Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015; 72: 756-63.
